HLS Therapeutics (HLTRF) Stock Price, News & Analysis

Company Overview

HLS Therapeutics is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription products for niche therapeutic markets. Headquartered in Mississauga, Ontario, the company builds its portfolio through strategic licensing agreements and in-house development, with an emphasis on therapies that address unmet needs in neurology and rare disorders.

The company’s marketed offering includes treatments for neurological conditions, most notably primary periodic paralysis, for which it commercializes dichlorphenamide (Keveyis) in North America. HLS Therapeutics pursues a targeted approach, selecting products with established clinical profiles and clear regulatory pathways, and supports each launch with dedicated field teams and medical affairs activities.

HLS Therapeutics serves both the Canadian and U.S. markets, leveraging partnerships to extend its reach and optimize supply chains. The company’s leadership team comprises industry veterans with experience in specialty pharmaceuticals, regulatory affairs and commercial operations, guiding its efforts to expand its portfolio through disciplined business development and product lifecycle management.

Key Stats

• Today's Range: $2.99 to $3.01
• 50-Day Range: $3.00 to $3.42
• 52-Week Range: $2.98 to $4.02
• Volume: 5,000 shs
• Average Volume: 995 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:HLTRF
• CIK: N/A
• Web: www.hlstherapeutics.com
• Phone: 647-495-9000
• Fax: N/A
• Employees: 91
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A